Abbott Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Abbott Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 11.3% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.4% betragen.

Wichtige Informationen

11.3%

Wachstumsrate der Gewinne

11.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	0%
Wachstumsrate der Einnahmen	6.3%
Zukünftige Eigenkapitalrendite	21.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	17 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BASE:ABT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	47,978	7,952	8,963	10,927	20
12/31/2025	44,732	7,167	7,974	9,975	23
12/31/2024	41,724	5,984	10,469	11,488	21
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,148	4,492	6,549	N/A
6/30/2023	40,226	5,146	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	4,816	5,997	N/A
3/31/2018	28,445	365	4,966	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A
9/30/2013	20,275	961	N/A	3,202	N/A
6/30/2013	20,715	648	N/A	6,199	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ABTDas prognostizierte Gewinnwachstum (11.3% pro Jahr) liegt über der Sparquote (8.4%).

Ertrag vs. Markt: ABTDie Erträge des Unternehmens (11.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt AR (15.7% pro Jahr).

Hohe Wachstumserträge: ABTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ABTDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt AR (4.4% pro Jahr).

Hohe Wachstumseinnahmen: ABTDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ABTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.4%)

Abbott Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Laboratories Raises Earnings Guidance for 2022

Recent updates

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q2, 2023 Results on Jul 20, 2023

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Declares Quarterly Common Cash Dividend, Payable on August 15, 2023

Abbott Receives FDA Approval for Tactiflex Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott Receives FDA Clearance for Assert-IQ™? Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

Abbott Declares Quarterly Dividend, Payable on May 15, 2023

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Proclaim™ XR

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott and Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Abbott Laboratories to Report Q4, 2022 Results on Jan 25, 2023

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Abbott Laboratories Launches the Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain

Abbott Increases Quarterly Dividend, Payable Feb. 15, 2023

Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home

Abbott's Freestyle Libre(R) 2 System Has Positive Impacts on Glucose Levels and Quality of Life

Abbott Laboratories to Report Q3, 2022 Results on Oct 19, 2022

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

Abbott Declares Quarterly Common Dividend, Payable November 15, 2022

Abbott Announces Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery

Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of the Securities of Abbott Laboratories

The Portnoy Law Firm Files A Class Action Lawsuit Filed on Behalf of Investors Against Abbott Laboratories

New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

U.S. Food and Drug Administration Approves Abbott's New Spinal Cord Stimulation Device and Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

Abbott Laboratories Announces Executive Changes

Abbott Laboratories Raises Earnings Guidance for 2022

Abbott Laboratories Announces Availability of 3D Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms in Canada

Abbott Receives Fda's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression

Abbott Laboratories to Report Q2, 2022 Results on Jul 20, 2022

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2022

Abbott Announces Late-Breaking Clinical Data That Demonstrate the FreeStyle Libre 3 System

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Abbott Laboratories Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

Abbott Laboratories Announces New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

Abbott Receives FDA Clearance for Its Alinity™ m STI Assay

Abbott Laboratories Announces Results from the Persist-End Study

Abbott Laboratories Launches an Upgraded Version of its Neurosphere™ Mypath™ Digital Health App

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie